InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.000 0.065 (3.36%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,597 Appendix 4C - quarterly 29 Apr 2008 7:30PM $0.735 $2.000 risen by 172.11%
$2,597 Cells Show Sustained Effect for Knee Osteoarthritis 17 Apr 2008 11:41AM $0.630 $2.000 risen by 217.46%
$2,597 Spinal Fusion Clinical Program Update 9 Apr 2008 8:57AM $0.680 $2.000 risen by 194.12%
$2,597 U.S. Heart Attack Trial Update 7 Apr 2008 9:54AM $0.660 $2.000 risen by 203.03%
$2,597 Half Yearly Report and Accounts 27 Feb 2008 10:24AM $0.700 $2.000 risen by 185.71%
$2,597 Agreement with Abbott for Stem Cell Heart Failure Therapy 19 Feb 2008 10:01AM $0.835 $2.000 risen by 139.52%
$2,597 Bone Repair Trial Results Show Stem Cells Speed Up Healing 13 Feb 2008 9:06AM $0.830 $2.000 risen by 140.96%
$2,597 Appendix 4C - quarterly 31 Jan 2008 4:47PM $0.915 $2.000 risen by 118.58%
$2,597 Mesoblast Raises New Capital to Expand Clinical Programs 10 Dec 2007 10:11AM $1.300 $2.000 risen by 53.85%
$2,597 Trading Halt 6 Dec 2007 1:52PM n/a $2.000 n/a
$2,597 Appendix 4C - quarterly 31 Oct 2007 3:19PM $1.400 $2.000 risen by 42.86%
$2,597 Preliminary Final Report 31 Aug 2007 8:27AM $1.525 $2.000 risen by 31.15%
$2,597 Stem Cells Protect Knee Cartilage in Osteoarthritis 20 Aug 2007 9:25AM $1.740 $2.000 risen by 14.94%
$2,597 Successful Clinical Outcomes in Cell Heart Trial 10 Aug 2007 8:39AM $1.950 $2.000 risen by 2.56%
$2,597 Appendix 4C - quarterly 27 Jul 2007 5:45PM $2.020 $2.000 fallen by 0.99%
$2,597 Mesoblast Begins Vertebral Disc Cartilage Program 24 Jul 2007 10:37AM $2.000 $2.000 fallen by 0%
$2,597 Mesoblast Begins Trials Using Off The Shelf Stem Cells 16 Jul 2007 9:31AM $2.000 $2.000 fallen by 0%
$2,597 Strong Interim Results in Fracture Repair Trial 18 Jun 2007 10:43AM $2.180 $2.000 fallen by 8.26%
$2,597 FDA Clearance to Begin Heart Attack Stem Cell Trial 2 May 2007 9:48AM $2.240 $2.000 fallen by 10.71%
$2,597 Commitments Test Entity - Third Quarter Report 30 Apr 2007 4:45PM $2.330 $2.000 fallen by 14.16%
$2,597 FDA Submission Filed For Heart Attack Trials 2 Apr 2007 8:41AM $2.190 $2.000 fallen by 8.68%
$2,597 Road to United States Product Registration 7 Mar 2007 10:21AM $2.010 $2.000 fallen by 0.50%
$2,597 Half Yearly Report & Accounts 20 Feb 2007 4:45PM $2.010 $2.000 fallen by 0.50%
$2,597 Cell Patents for Cardiac Disease- New Clinical Opportunities 6 Feb 2007 8:38AM $2.300 $2.000 fallen by 13.04%
$2,597 Commitments Test Entity - Second Quarter Report 31 Jan 2007 4:40PM $2.200 $2.000 fallen by 9.09%

1126 - 1150 of 1190 results

Page 46 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.